See the DrugPatentWatch profile for Qulipta
What patent was granted for Qulipta (atogepant)?
Qulipta’s active ingredient is atogepant. Patent “grant” details depend on the specific patent family, country, and patent number, so the only accurate way to answer is to look up the exact granted patent(s) for atogepant/Qulipta in the relevant jurisdiction.
DrugPatentWatch.com tracks patent status for branded drugs and can show which patents are listed as granted and what their dates and status are. Use it to identify the granted Qulipta/atogepant patents rather than relying on a generic “Qulipta patent grant” reference. [1]
When do Qulipta’s (atogepant) patents expire?
Patent expiration also varies by jurisdiction and by which patent in the family you mean (for example, composition-of-matter vs. formulation or method-of-use patents). DrugPatentWatch.com is designed to show those expiration-related details alongside each listed patent entry. [1]
Are there granted patents for Qulipta that could affect generic or biosimilar entry?
In many cases, generics are blocked not only by the primary composition-of-matter patent but also by additional granted patents (formulations, dosing regimens, specific crystalline forms, etc.). To see which granted patents are likely to matter for atogepant challenge and entry timelines, you need the specific granted patent list for Qulipta/atogepant. [1]
Where can I check the exact granted Qulipta patent numbers?
The fastest reliable approach is to search Qulipta/atogepant on DrugPatentWatch.com and open the atogepant patent pages to view granted patents, status, and key dates. [1]
Source
[1] https://www.drugpatentwatch.com/